News

Find here our press releases and most relevant news

News

Press release
- 27.05.2026

Positive Topline Results from BRIUMVIยฎ Phase 3 ENHANCE Trial

Press release
- 17.02.2026

Long-Term/Five-Year Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI ยฎ in Relapsing Multiple Sclerosis

Press release
- 12.01.2026

Neuraxpharm enhances ADHD treatment options in Europe with two launches

Announcement
- 23.12.2025

End of Year Recap

Press release
- 27.11.2025

Neuraxpharm and mjn-neuro announce plans to launch EPISERASยฎ, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

News

Press release
- 27.05.2026

Positive Topline Results from BRIUMVIยฎ Phase 3 ENHANCE Trial

Press release
- 17.02.2026

Long-Term/Five-Year Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI ยฎ in Relapsing Multiple Sclerosis

Press release
- 12.01.2026

Neuraxpharm enhances ADHD treatment options in Europe with two launches

Announcement
- 23.12.2025

End of Year Recap

Press release
- 27.11.2025

Neuraxpharm and mjn-neuro announce plans to launch EPISERASยฎ, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

Press release
- 02.10.2025

Neuraxpharm strengthens multiple sclerosis portfolio with the launch of Riulvyยฎ (tegomil fumarate)

Press release
- 24.09.2025

New Data for BRIUMVIยฎ Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Announcement
- 11.08.2025

Neuraxpharm signs an exclusive distribution agreement with Pendopharmยฎ for Buccolamยฎ in Canada

Announcement
- 10.06.2025

Buccolamยฎ: expanding access, empowering care in epilepsy

Media Enquiries

If you are a journalist with a media enquiry, please contact the Neuraxpharm media office by filling the contact form.

The content you are about to see is intended for the exclusive use of media and healthcare professionals.

Please confirm whether you are a media or a healthcare professiona

The content you are about to see is intended for the exclusive use of media and healthcare professionals.

Please confirm whether you are a media or a healthcare professional